Kengrexal

Cangrelor tetrasodium, the active ingredient in Kengrexal, is a P2Y12 platelet inhibitor presented as an intravenous formulation for use in hospital settings. It provides rapid, reversible inhibition of platelet activation and aggregation, allowing clinicians to control anticoagulation during and after percutaneous coronary intervention (PCI) and to reduce the risk of clot formation in the coronary arteries.

GNH USA supplies Kengrexal as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and specialized cardiac care centres worldwide.

Kengrexal, a P2Y12 platelet inhibitor, is employed in the cardiovascular interventional pathway to mitigate clot‑related complications associated with coronary procedures. It is specifically indicated for patients undergoing percutaneous coronary intervention, where timely platelet inhibition is critical.

- Percutaneous coronary intervention (PCI): prevention of thrombotic events during and after the procedure.

Cangrelor is associated with several adverse reactions that clinicians monitor during therapy.

Common Side Effects: - Dyspnea: shortness of breath occurring during infusion. - Nausea: mild to moderate gastrointestinal discomfort. - Chest discomfort: transient chest pain not related to myocardial ischemia. - Hypotension: mild drop in blood pressure. - Mild bleeding at catheter sites.

Serious or Rare Side Effects: - Severe bleeding: life‑threatening hemorrhage requiring intervention. - Anaphylactic reaction: rare hypersensitivity with rash, swelling, or airway compromise. - Thrombocytopenia: significant drop in platelet count. - Myocardial infarction: rare occurrence despite antiplatelet therapy. - Cardiac arrest: extremely rare but reported in clinical settings.

When using Kengrexal, several safety considerations should be observed to minimize risks.

- Assess bleeding risk: evaluate patient history for recent surgery or hemorrhagic disorders. - Monitor platelet function: perform laboratory tests to confirm adequate inhibition. - Avoid concurrent strong antithrombotics: limit use with other P2Y12 inhibitors or glycoprotein IIb/IIIa blockers. - Adjust for renal impairment: consider reduced clearance in severe kidney dysfunction. - Pregnancy and lactation: use only if potential benefit justifies potential risk. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Cangrelor may interact with other agents that affect hemostasis or platelet function.

Major Interactions (Avoid): - Concurrent P2Y12 inhibitors (e.g., clopidogrel, prasugrel): markedly increased bleeding risk. - Glycoprotein IIb/IIIa inhibitors (e.g., abciximab): additive antiplatelet effect leading to severe hemorrhage. - Oral anticoagulants (warfarin, DOACs): heightened overall anticoagulation.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may exacerbate gastrointestinal bleeding. - CYP3A4 inducers (e.g., rifampin): potential reduction in antiplatelet effect. - Heparin: combined use may require closer coagulation monitoring.